| Anna Lee Brown, LCSW | |
|
10301 Mayo Dr, Barling, AR 72923-1660 | |
| (479) 494-5760 | |
| (479) 484-8142 |
| Full Name | Anna Lee Brown |
|---|---|
| Gender | Female |
| Speciality | Social Worker - Clinical |
| Location | 10301 Mayo Dr, Barling, Arkansas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1598793481 | NPI | - | NPPES |
| 5S890 | Other | AR | BLUE CROSS |
| 19820200000 | Other | AR | QUALCHOICE QCA |
| 19518 | Other | AR | MHN |
| Mailing Address | Practice Location Address |
|---|---|
| Anna Lee Brown, LCSW 4253 N Crossover Rd, Fayetteville, AR 72703-4593 Ph: (479) 521-5731 | Anna Lee Brown, LCSW 10301 Mayo Dr, Barling, AR 72923-1660 Ph: (479) 494-5760 |
News Archive
Noble metals such as platinum and palladium are becoming increasingly important because of growth in environmentally friendly applications such as fuel cells and pollution control catalysts. But the world has limited quantities of these materials, meaning manufacturers will have to rely on efficient recycling processes to help meet the demand.
Mylan Inc. today announced that its subsidiary Mylan Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for Atorvastatin Calcium Tablets, 10 mg, 20 mg, 40 mg and 80 mg.
Children with juvenile idiopathic arthritis have a two to threefold increased risk of developing cancer compared to similarly-aged children without JIA, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta. The same study also reported no cases of cancer in children with JIA who were exposed to anti-TNF therapy.
Eisai Inc. announced today that its parent company Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) and Halozyme Therapeutics, Inc. (Headquarters: San Diego, California, President and CEO: Dr. Helen Torley) have signed a clinical collaboration agreement to evaluate Eisai's agent eribulin mesylate (brand name: Halaven, "eribulin") in combination with Halozyme's investigational drug PEGPH20 (PEGylated recombinant human hyaluronidase) in first line HER2-negative metastatic breast cancer.
Only 53 percent of newly diagnosed breast cancer patients who were at high risk of carrying a BRCA 1 or BRCA 2 mutation - based on age, diagnosis, and family history of breast or ovarian cancer - reported that their doctors urged them to be tested for the genes, according to a research team from the Perelman School of Medicine at the University of Pennsylvania.
› Verified 5 days ago
Angela Larimer, Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1311 Fort Street, Barling, AR 72923 Phone: 479-452-5040 | |
Kelly Vansell, Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1311 Fort Street, Barling, AR 72923 Phone: 479-452-5040 | |
Simon Edward Ellis Jr., Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1311 Fort Street, Barling, AR 72923 Phone: 479-452-5040 | |
Kaye Pryor, Clinical Social Worker Medicare: May Accept Medicare Assignments Practice Location: 1311 Fort Street, Barling, AR 72923 Phone: 479-452-5040 | |
Hien T Vu, LMSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 815 Fort St Ste A, Barling, AR 72923 Phone: 479-494-5700 Fax: 479-484-8142 | |
Robert J Bronson, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 10301 Mayo Dr, Barling, AR 72923 Phone: 479-494-5700 Fax: 479-494-9992 |